HLN-WI / Haleon's reported strategic M&A dismissed as 'highly unlikely' and unwanted headache

Haleon (LON: HLN) share price has moved sideways in the past few days as GlaxoSmithKline (GSK) continued selling stake in the company. The shares also more_horizontal

Haleon PLC (LSE:HLN, NYSE:HLN) has grown profits more slowly in the first quarter of 2023 amid higher costs and unhelpful currency swings. The Volatro more_horizontal

Haleon PLC (LSE:HLN, NYSE:HLN) has "achievable" sales targets but it may struggle to meet the market's expected level of profit margins, according to more_horizontal

Haleon PLC (LSE:HLN, NYSE:HLN) will find it difficult to get a significant re-rating for its shares, reckons Deutsche Bank.  Following a meeting wi more_horizontal

Haleon PLC (LSE:HLN, NYSE:HLN) shares fell to close to a three-month low after the consumer health group posted encouraging full-year numbers but ana more_horizontal

Haleon PLC (LSE:HLN, NYSE:HLN) declared an inaugural dividend after its merger from GSK last year as price increases and efficiencies enabled increase more_horizontal

Haleon PLC's (LSE:HLN, NYSE:HLN) reported interest in large 'strategic scale' acquisitions, such as with Sanofi's consumer arm, have been panned by more_horizontal

Barclays has upgraded its rating on Haleon PLC (LSE:HLN, NYSE:HLN) after Zantac-related litigation in the US was dismissed, meaning it will not proc more_horizontal